A review on thyroid cancer during pregnancy: Multitasking is required  by Khaled, Hussein et al.
Journal of Advanced Research (2016) 7, 565–570Cairo University
Journal of Advanced ResearchREVIEWA review on thyroid cancer during pregnancy:
Multitasking is required* Corresponding author. Tel.: +20 122 215 1040; fax: +20 2 5252953.
E-mail address: khussein528@gmail.com (H. Khaled).
Peer review under responsibility of Cairo University.
Production and hosting by Elsevier
http://dx.doi.org/10.1016/j.jare.2016.02.007
2090-1232  2016 Production and hosting by Elsevier B.V. on behalf of Cairo University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Hussein Khaled a,*, Nasr Al Lahloubi a, Noha Rashad baDepartment of Medical Oncology, National Cancer Institute, Cairo University, Egypt
bDepartment of Medical Oncology, Military Armed Hospital Caner Center, Cairo, EgyptG R A P H I C A L A B S T R A C TA R T I C L E I N F O
Article history:
Received 26 January 2016
Received in revised form 19 February
2016
Accepted 23 February 2016
Available online 2 March 2016
Keywords:
Thyroid cancerA B S T R A C T
Thyroid cancer is the second most common cancer diagnosed during pregnancy after breast
cancer. The goal of management is to control malignancy and prevent maternal and fetal
complications as a result of maternal hypothyroidism. The role of female sex hormones as an
etiologic factor was investigated, with no clear association. Pregnancy can cause an increase
in size of a previously existed thyroid nodule through the structural similarity between TSH
and BHCG, and the normally expressed estrogen receptors on thyroid gland cells. Effect of
pregnancy on development and prognosis of differentiated thyroid malignancies (papillary
and follicular) has also been studied. The prognosis of thyroid cancer is not worse in patients
diagnosed during pregnancy or those who got pregnant after curative treatment. Termination
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Radioactive iodineof pregnancy is not indicated at all, surgery can be delayed till after delivery except in rapidly
growing aggressive tumors. While radioactive iodine ablation is absolutely contra-indicated,
the new systemic therapies are not well studied during pregnancy. However, almost all these
new agents are classified as FDA category C or D and are better to be avoided. The effect of
pregnancy on other types of thyroid cancer (medullary and anaplastic thyroid tumors) is not
well studied because of very low incidence with pregnancy. The endocrinological management
of thyroid cancer during pregnancy is of utmost importance. The hypothyroidism after total
thyroidectomy can cause fetal hypothyroidism. Therefore, the management of thyroid cancer
related to pregnancy needs a multidisciplinary team.
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access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Thyroid cancer is the second most common cancer diagnosed
during pregnancy [1]. The management of thyroid cancer inthis situation has multiple goals: to control the malignancy,
overcome the hormonal disturbances after thyroidectomy
and to avoid drawbacks on fetus as a result of maternal
hypothyroidism [2]. Total or near total thyroidectomy is the
standard of care for patients diagnosed with thyroid cancer,
followed by radioactive iodine administration as an adjunctive
treatment in differentiated thyroid tumors.
Pregnancy is an absolute contraindication for radioactive
iodine administration. The timing of surgery, the impact of
pregnancy on prognosis of thyroid cancer and monitoring of
pregnant women with thyroid cancer are important points to
be discussed while treating a case presented with thyroid can-
cer related to pregnancy [3].
The aim of this article is to revise the medical literature for
data related to this clinical situation, aiming to provide
answers for questions regarding management of such patients.Epidemiology and risk factors
The incidence of thyroid cancer is rising all over the world [4].
The increase is affecting all ethnic and age groups with an
increased risk among women below 45 years old [5]. The
increase may have some geographical variation with significant
increase in Eastern Europe since the Chernobyl nuclear power
plant accident and areas affected by radioactive fallout as
Belarus and Ukraine [6]. The increase in incidence is not
accompanied by an increase in mortality; this reflects the indo-
lent nature of the disease, as the rise in cause specific mortality
rates is expected many years later [4].
Whether this increase in incidence is a true increase or
inflated by increase in diagnosis has been debated. Some
authors attribute the increase in incidence to the increased uti-
lization of sensitive radiological maneuvers i.e. ultrasound in
health care, leading to diagnosis of lesions that otherwise
was going to pass unnoticed. This premise can explain the
increased incidence of small tumors. The increase in incidence
of large tumors and the almost exclusive increase in papillary
histopathology subtype can argue against the premise of false
increase due to early detection and support the premise of a
true increase in incidence worldwide [7].
Women are affected by thyroid cancer more than men as
female to male ratio may reach to 3–1. Thyroid cancer is the
second most common malignancy during pregnancy, preceded
only by breast cancer with an incidence of 14 per 100,000 live
births [1]. History of exposure to ionizing radiation, and iodine
deficiency are well established risk factors for thyroid cancer.
MEN2 is a genetic syndrome that affects 1–2% of all the
Thyroid cancer and pregnancy 567patients with thyroid cancer [4]. The female dominance and
age specific increase in incidence in women during the child-
bearing period suggested a possible role of sex hormones in
developing thyroid cancer especially differentiated thyroid
cancer (papillary and follicular thyroid cancers).
A pooled analysis of 14 case control studies included a total
of 2247 female patients suggested a weak association of repro-
ductive and menstrual factor as age at menarche, age at first
pregnancy and menopause with the risk of thyroid cancer
[8]. However, the hypothesis of this association has been also
studied in large prospective cohorts with contradictory results.
The California teachers cohort study investigated the effect of
menstrual, reproductive and other hormonal factors including
exogenous hormones intake on developing papillary thyroid
cancer. This prospective cohort, which included 117,646
women has suggested an association between late age at
menarche, longer menstrual cycle (more than 30 days) and
the increased risk of papillary thyroid cancer [9]. On the other
hand, the EPIC study, which is also a prospective cohort study
with a large sample size (345,157 women), followed for a med-
ian of 11 years did not find strong association between repro-
ductive factors and the risk of developing thyroid cancer [8].
Both studies, however, identified a positive association
between recent pregnancy (within 5 years of cohort enroll-
ment) and thyroid cancer risk [9,10].
A meta-analysis was conducted to solve this issue, with 21
studies including 406,329 cases. This meta-analysis suggested
a strong association of parity (P3 pregnancies) with the risk
of thyroid cancer. It confirmed the previously noted observa-
tion of transient increased risk of thyroid cancer with recent
pregnancy (65 years since the last pregnancy) [11].Pregnancy and thyroid
Thyroid gland size normally increases by 30% during the first
and third trimesters of pregnancy. TSH level fluctuates during
pregnancy, as it decreases during the first trimester and then
returns to normal. As the fetal thyroid cannot concentrate
iodine till week 12 of gestation, maternal T4 is the only source
of thyroid hormones for the fetus [12]. For monitoring of thy-
roid function during pregnancy, special reference ranges in
relation to gestational age are used to avoid misinterpretation
of thyroid function tests. This is of paramount importance in
monitoring patients known to have thyroid cancer as TSH
level guides suppressive treatment dose adjustment with levo-
thyroxin [2,3,12].
The effect of pregnancy on thyroid gland could be
explained by two main mechanisms, the increase in the level
of HCG and the increase in circulating estrogen level. As both
TSH and HCG are glycoprotein hormones with similar struc-
ture and encoded by the same gene [13], HCG stimulates TSH
receptors and leads to increase in the activity of thyroid gland.
TSH level subsequently decreases mainly during the first
12 weeks of gestation then back to normal [3,12,14]. HCG
stimulating effect on thyroid gland can be noted in diseases
causing very high levels of HCG as gestational trophoblastic
diseases [15], with less than 10% of these patients presenting
with manifest hyperthyroidism and thyrotoxicosis in rare cases
[16].
Estrogen level exerts its effect through more complicated
mechanisms; it has an indirect effect through increasing theserum thyroxin binding globulin. The direct effect is through
estrogen receptors presented on thyroid gland cells [17]. ERa
and ERb are intracellular nuclear receptors that exist in
normal and neoplastic thyroid cells. Estradiol binding to
ERa enhances cell proliferation while ERb inhibits these
effects and induces apoptosis [18,19]. Some recent studies
showed different levels of expression of ERa and a decrease
in increase in ERb in malignant thyroid cells in comparison
with normal cells [20]. Estrogen DNA adducting with unbal-
anced estrogen metabolism in patients with thyroid cancer
was also reported [21]. Another study suggested an association
between ER expression and aggressiveness of disease at presen-
tation and relapse [22].
Effect of pregnancy on thyroid cancer prognosis
A thyroid nodule is defined as a discrete lesion in the thyroid
gland that is radiologically distinct from the surrounding par-
enchyma. Thyroid nodular diseases are common during preg-
nancy, with increase in newly developed nodules and also
increase in size and number of previously existed nodules
[23]. Thyroid cancer related to pregnancy is defined as differen-
tiated thyroid cancer (DTC) diagnosed during pregnancy or
within 12 months of childbirth [24].
The effect of pregnancy on prognosis of DTC has been
studied to answer a pivotal question, if the pregnancy can wor-
sen the prognosis of DTC or cause a relapse in a previously
treated patient. There is an extensive amount of literature dis-
cussing the effect of pregnancy on thyroid cancer. To find a
final conclusion, a systematic review published in 2011 revised
4 main studies to evaluate the effect of pregnancy on recur-
rence/persistence of disease as well as overall survival [24].
The primary outcome of these studies was different; in two
studies the primary outcome was overall survival, in the third
one, the primary outcomes were recurrent disease and death
related to thyroid cancer, and in the fourth study the primary
outcome was recurrent or persistent disease. Two of these 4
studies did not suggest a negative effect of pregnancy on over-
all survival [25,26]. The third study [27] showed also no
increase in recurrence rates or disease related mortality, while
the last one found an association between pregnancy and per-
sistent or recurrent disease [22].
As the included studies were heterogeneous in methodology
and with different primary outcome, so a meta-analysis could
not be done, and the authors attributed this difference in out-
comes to the difference in outcome measurement predictors, as
this last trial used the level of Tg level, which is more sensitive
and was not used by the other trials. While this is the case for
DTC, the effect of pregnancy on micro papillary thyroid
cancer carcinomas, which are defined as having a maximum
diameter of 610 mm, was evaluated in a small retrospective
study. This study indicated that its size may increase during
pregnancy [28].
Pregnancy after treatment for DTC
Another question is the effect of pregnancy on previously trea-
ted patient with DTC; a retrospective study done on 72
patients previously treated with thyroidectomy and radio-
active iodine ablation was done; 36 of the study population
got pregnant after treatment and 36 were non-pregnant; and
568 H. Khaled et al.the outcomes of treatment and the prognosis (in terms of
scintigraphic relapse and metastasis, ultrasonographic relapse,
lymphadenopathy and stage change at the beginning and at
the end of follow-up) were not compromised with pregnancy
[29]. This comes in partial agreement with previously published
study by Hirsch et al. [30]. They concluded that pregnancy did
not cause disease recurrence in papillary thyroid cancer sur-
vivors who had no structural or biochemical evidence of dis-
ease persistence at the time of conception, while in the
presence of such evidence, disease progression might occur
during pregnancy. Although the outcomes of treatment are
not compromised by pregnancy, it is advised to avoid preg-
nancy for 12 months after radioactive iodine treatment to
ensure remission [31].
Diagnostic approach and risk assessment of thyroid nodule
during pregnancy
Till now, there is no consensus regarding screening for thyroid
dysfunction neither during pregnancy nor for thyroid nodules
[12,32]. If a thyroid nodule is found during physical examina-
tion or accidently during an ultrasound examination, it should
be assessed for suspicious of malignancy. The following crite-
ria indicated the need for fine needle aspiration cytology:
hypo-echogenic irregular nodule margins, absent peripheral
halo of nodule, increased intra-nodular vascularization,
presence of latero-cervical adenopathies, presence of microcal-
cifications, nodules taller than wider, and presence of microcal-
cifications [3,32].
Fine needle aspiration cytology is safe and convenient
method for assessing a thyroid nodule; both ATA (American
Thyroid Association) and ENDO (The Endocrine Society) rec-
ommend the performance of the procedure in this situation.
Interpretation of its results should be done using Bethesda
classification criteria for cytological assessment [3]. As
previously mentioned, thyroid scan is contraindicated.
Timing of surgery
The standard primary treatment for patients with thyroid can-
cer remains total or near total thyroidectomy. In a pregnant
woman, both maternal and fetal outcomes shall be considered
before taking the decision of surgery. As previously mentioned,
there is no evidence to support termination of pregnancy when
the diagnosis of differentiated thyroid cancer is performed. The
Endocrine Society for pregnancy-related differentiated thyroid
cancer has recommended thyroidectomy after delivery for
patients with no evidence of advanced disease or without rapid
progression, and thyroidectomy in the second trimester of preg-
nancy for the others. Radioactive iodine should only be given
after delivery and the ending of breast feeding [22]. Thus, and
as it seems there is no negative impact for pregnancy on prog-
nosis of differentiated thyroid cancer, the delay of surgery
seems a reasonable approach to avoid postoperative complica-
tions. However, in some patients diagnosed during the first tri-
mester of pregnancy, tumors may show aggressive behavior
(aggressive or locally advanced histology, metastatic cervical
lymph nodes diagnosed by cytology, severe compressive symp-
toms and the significant growth of a malignant nodule with
>50% in volume or >20% in diameter in two dimensions).
In such situations, surgery should be carried out during secondtrimester and not be postponed till delivery [3,33]. Surgery
during the second trimester is considered safe with no major
morbidity either fetal or maternal. However, Kuy [34] and
colleagues reported a higher incidence of postoperative compli-
cations in comparison with non-pregnant women submitted to
thyroidectomy in terms of fetal, maternal, and surgical compli-
cations. This was clear in terms of in-hospital mortality, median
length of stay, and hospital costs.
For patients diagnosed during the third trimester,
surgery could be safely delayed after surgery to avoid the
expected complications of surgery in this late period of
pregnancy, as premature labor and hypotension during sur-
gery caused by compression of gravid uterus on grand vessels
[3,33,35].Radioactive iodine (RAI) ablative therapy
Aiming to reduce recurrence and achieve long term control for
distant metastatic disease, radioactive iodine ablation with I131
usually follows surgery in most patients with thyroid cancer.
The patients planned to receive RAI should be tested for preg-
nancy before deciding treatment [36]. Exposure to radioactive
iodine during pregnancy is contraindicated, and the hazards of
this exposure include fetal hypothyroidism and cognitive disor-
ders and mental retardation [35]. In patients requiring RAI
therapy after delivery, breast feeding shall be stopped at least
6 weeks before ablative therapy and mothers should be advised
against nursing [2]. There is no evidence that RAI can affect
fertility or affect subsequent pregnancy [3], and a conservative
approach is to avoid pregnancy for 12 months after RAI abla-
tive therapy to ensure remission and attain adequate thyroid
hormone replacement [31].Therapy with levothyroxine (LT4)
A patient with thyroid cancer related to pregnancy needs
LT4 treatment for different indications, as a suppressive treat-
ment for those who were decided to postpone surgery till
second trimester or after delivery, as a replacement therapy
for a survivor of thyroid cancer after thyroidectomy, and as
a suppressive therapy for patients with residual disease.
If cytopathology confirmed the diagnosis with DTC and the
surgery was decided to be post-partum, it is advisable to start
treatment with LT4. Suppressive treatment with LT4 aims to
keep TSH level below 0.1–1 mU/l, with monthly monitoring
of TSH and T4 levels [3,37].
As maternal hypothyroidism has serious drawbacks on the
fetal development, so in a patient with history of thyroidec-
tomy LT4 therapy is mandatory. Thyroxin hormone require-
ments increase by 20–30% during pregnancy, and the dose
of levothyroxine should be adjusted within reference range
specific for pregnancy. Other dietary supplements were used
during pregnancy as iron and calcium can affect LT4 absorp-
tion, so close monitoring of thyroid function is mandatory
[3,37]. If surgery was done during pregnancy, LT4 therapy
should be started immediately after surgery [3]. In a patient
under suppressive treatment with LT4 for a residual/persistent
disease, the treatment in this case has a goal of keeping the
TSH level below 0.1 mU/l indefinitely [33].
Thyroid cancer and pregnancy 569Systemic therapy for thyroid cancer during pregnancy
DTC refractory to RAI can be treated with tyrosine kinase
inhibitors (TKIs). Motesanib diphosphate, axitinib, sorafenib,
sunitinib and pazopanib are accepted treatment options. For
medullary carcinoma of thyroid, vandetanib, cabozantinib,
and lenvatinib are also treatment options [38].
The safety of these drugs during pregnancy and lactation
was not studied in humans, with data available only from
animal studies. FDA classifies sorafenib [39], sunitinib [40],
axitinib [41] and pazopanib [42] as Category D. Safety
concerns also imply the toxicities of these agents, vandetanib
[43], lenvatinib [44] and cabozantinib [45] are also categorized
as Category D, and vandetanib is known to induce cardiotox-
icity that could be irreversible. Finally, chemotherapy either as
a single agent or as a polychemotherapy has been abandoned
due to poor results [37].
Conclusions
The management of thyroid cancer during pregnancy is a
difficult clinical problem and must be managed through a
multidisciplinary team using guidelines adopted by American
Thyroid Association (ATA) and The Endocrine Society
(ENDO). As radioactive iodine is contraindicated during
pregnancy, ultrasound examination of thyroid gland is recom-
mended in suspicious lesions with FNAC if needed for highly
suspicious lesions. Termination of pregnancy is not indicated
and surgical intervention can be delayed after delivery, while
the role of TKIs in this population is poorly studied.Conflict of Interest
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